QDVO is concentrated in large-cap growth, especially tech, with high income potential but notable liquidity and volatility ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Pursuant to S. 24 of the Capital Markets Act, we hereby publish data on debtor composition in bonds issued by Jyske Realkredit. Please find the data in the attached file. The information will also be ...

Preliminary data on early redemptions (prepayments) Pursuant to S. 24 of the Capital Markets Act, we hereby publish preliminary data on early redemptions (prepayments) in bonds issued by Jyske ...